Stability and compatibility of anakinra with intravenous cimetidine hydrochloride or famotidine in 0.9% sodium chloride injection.
We designed a study to evaluate the stability and compatibility of anakinra (recombinant human interleukin-1 receptor antagonist) with cimetidine hydrochloride or famotidine in 0.9% sodium chloride injection during a 4-h period at room temperature (22 degrees C) and light. Anakinra was diluted in 0.9% sodium chloride to concentrations of 4 and 36 mg/ml. At each concentration, anakinra was mixed with 3 mg/ml cimetidine or with 1 mg/ml famotidine, in a 50:50 proportion and stored in plastic culture vials with polypropylene caps. The mean concentrations of anakinra, cimetidine hydrochloride, and famotidine exceeded 95% of initial concentrations throughout the study. No changes were noted in the physical appearance, pH, or the chromatograms during the study period. Thus, anakinra appears to be stable and compatible with cimetidine hydrochloride or famotidine when diluted into 0.9% sodium chloride injection for 4 h at ambient room temperature and light.
Nahata
M C
MC
College of Pharmacy, Ohio State University, Columbus 43210, USA.
Morosco
R S
RS
Sabados
B K
BK
Weber
T R
TR
D002851:Chromatography, High Pressure Liquid; D002927:Cimetidine / Q000737:chemistry / Q000378:metabolism*; D004338:Drug Combinations; D004347:Drug Interactions; D004355:Drug Stability; D015738:Famotidine / Q000737:chemistry / Q000378:metabolism*; D006863:Hydrogen-Ion Concentration; D053590:Interleukin 1 Receptor Antagonist Protein; D008027:Light; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D012795:Sialoglycoproteins / Q000737:chemistry / Q000378:metabolism*; D012965:Sodium Chloride / Q000737:chemistry / Q000378:metabolism; D013696:Temperature
D004338:Drug Combinations; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; D012965:Sodium Chloride; D015738:Famotidine; D002927:Cimetidine